Pharmaceuticals (Mar 2022)

Design, Synthesis, and Cytotoxicity and Topoisomerase I/IIα Inhibition Activity of Pyrazolo[4,3-<i>f</i>]quinoline Derivatives

  • Chhabi Lal Chaudhary,
  • Seungyun Ko,
  • Chaerim Lee,
  • Yerin Kim,
  • Chanhyun Jung,
  • Soonsil Hyun,
  • Youngjoo Kwon,
  • Jong-Soon Kang,
  • Jae-Kyung Jung,
  • Heesoon Lee

DOI
https://doi.org/10.3390/ph15040399
Journal volume & issue
Vol. 15, no. 4
p. 399

Abstract

Read online

With the several targets of cancer treatment, inhibition of DNA topoisomerase activity is one of the well-known focuses in cancer chemotherapy. Here, we describe the design and synthesis of a novel series of pyrazolo[4,3-f]quinolines with potential anticancer/topoisomerase inhibition activity. Forty newly designed pyrazolo[4,3-f]quinoline derivatives were synthesized via inverse imino Diels–Alder reaction. The antiproliferative activity of the synthesized derivatives was initially measured in the human NUGC-3 cancer cell line. Then, the selected compounds 1B, 1C, 1M, 2A, 2D, 2E, 2F, and 2R with higher activity among tested compounds were screened against six cancer cell lines, including ACHN, HCT-15, MM231, NCI-H23, NUGC-3, and PC-3. The results demonstrated that the compounds 1M, 2E, and 2P were most effective in all cancer cell lines exhibiting GI50 below 8 µM. Among them, 2E showed an equivalent inhibition pattern of topoisomerase IIα activity to that of etoposide, positive control at a 100 µM dose.

Keywords